The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies

[1]  P. Thall,et al.  Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.

[2]  D. Fruci,et al.  Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors , 2020, Frontiers in Immunology.

[3]  N. Tumino,et al.  Exploiting Human NK Cells in Tumor Therapy , 2020, Frontiers in Immunology.

[4]  D. Campana,et al.  NK cells for cancer immunotherapy , 2020, Nature Reviews Drug Discovery.

[5]  F. Mei,et al.  Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  R. Brentjens,et al.  Engineering strategies to overcome the current roadblocks in CAR T cell therapy , 2019, Nature Reviews Clinical Oncology.

[7]  C. Genova,et al.  Harnessing NK Cells for Cancer Treatment , 2019, Front. Immunol..

[8]  Charles H. Yoon,et al.  Discovery of specialized NK cell populations infiltrating human melanoma metastases. , 2019, JCI insight.

[9]  M. Bodman-smith,et al.  Granulysin: The attractive side of a natural born killer. , 2019, Immunology letters.

[10]  Z. Tian,et al.  Interleukin‐33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development , 2019, International journal of cancer.

[11]  Wei Zhang,et al.  Progranulin Promotes Melanoma Progression by Inhibiting Natural Killer Cell Recruitment to the Tumor Microenvironment. , 2019, Cancer letters.

[12]  Jeffrey S. Miller,et al.  Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside , 2019, Cancer Immunology Research.

[13]  S. Doberstein.  Bempegaldesleukin (NKTR-214): a CD-122-biased IL-2 receptor agonist for cancer immunotherapy , 2019, Expert opinion on biological therapy.

[14]  S. H. van der Burg,et al.  Monalizumab: inhibiting the novel immune checkpoint NKG2A , 2019, Journal of Immunotherapy for Cancer.

[15]  Musbahu M Sani,et al.  Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9 , 2019, Immunology.

[16]  Betty Y. S. Kim,et al.  Phagocytosis checkpoints as new targets for cancer immunotherapy , 2019, Nature Reviews Cancer.

[17]  I. Melero,et al.  Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.

[18]  Z. Tian,et al.  NK Cell Dysfunction and Checkpoint Immunotherapy , 2019, Front. Immunol..

[19]  Kongming Wu,et al.  Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity , 2019, Molecular Cancer.

[20]  M. Cam,et al.  Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment , 2019, Cancer Immunology Research.

[21]  N. Jahchan,et al.  Tuning the Tumor Myeloid Microenvironment to Fight Cancer , 2019, Front. Immunol..

[22]  D. Gao,et al.  The miR-561-5p/CX3CL1 Signaling Axis Regulates Pulmonary Metastasis in Hepatocellular Carcinoma Involving CX3CR1+ Natural Killer Cells Infiltration , 2019, Theranostics.

[23]  T. Waldmann,et al.  First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. , 2019, Blood advances.

[24]  Ying Yang,et al.  Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors , 2019, Cancers.

[25]  Janice M Reichert,et al.  Bispecific antibodies: a mechanistic review of the pipeline , 2019, Nature Reviews Drug Discovery.

[26]  Yu Wang,et al.  Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation , 2019, Frontiers of Medicine.

[27]  H. Young,et al.  IFN-γ: A cytokine at the right time, is in the right place. , 2019, Seminars in immunology.

[28]  S. Matosevic,et al.  Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy , 2019, Cancers.

[29]  M. Hurwitz,et al.  A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. , 2019, Cancer discovery.

[30]  Melissa J. Davis,et al.  A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients , 2019, Cancer Immunology Research.

[31]  M. Colonna,et al.  The Natural Cytotoxicity Receptors in Health and Disease , 2019, Front. Immunol..

[32]  D. Finlay,et al.  Immunometabolism and natural killer cell responses , 2019, Nature Reviews Immunology.

[33]  N. Tumino,et al.  Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing , 2019, Front. Immunol..

[34]  D. Olive,et al.  Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function , 2019, Front. Immunol..

[35]  D. Campana,et al.  Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. , 2019, The Journal of clinical investigation.

[36]  L. Qing,et al.  Increased CX3CL1 mRNA expression level is a positive prognostic factor in patients with lung adenocarcinoma , 2019, Oncology letters.

[37]  R. Schreiber,et al.  Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. , 2019, Cold Spring Harbor perspectives in biology.

[38]  M. Cairo,et al.  Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors , 2019, Front. Oncol..

[39]  C. Rooney,et al.  NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors , 2019, Cancer Immunology Research.

[40]  R. Johnson,et al.  Gene Regulatory Programs Conferring Phenotypic Identities to Human NK Cells , 2019, Cell.

[41]  A. Gonzalez-Perez,et al.  NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival , 2018, Clinical Cancer Research.

[42]  M. Smyth,et al.  Cancer immunoediting and resistance to T cell-based immunotherapy , 2018, Nature Reviews Clinical Oncology.

[43]  O. Lantz,et al.  Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells , 2018, Cell.

[44]  V. Cerundolo,et al.  NKG2A, a New Kid on the Immune Checkpoint Block , 2018, Cell.

[45]  M. Welters,et al.  NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines , 2018, Cell.

[46]  S. Beyaz,et al.  Metabolic reprogramming of natural killer cells in obesity limits antitumor responses , 2018, Nature Immunology.

[47]  C. Reis e Sousa,et al.  The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity , 2018, Trends in cancer.

[48]  Eric Vivier,et al.  High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice , 2018, Immunity.

[49]  S. Regis,et al.  Molecular Mechanisms Directing Migration and Retention of Natural Killer Cells in Human Tissues , 2018, Front. Immunol..

[50]  D. Budman,et al.  Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics , 2018, Molecular Medicine.

[51]  É. Vivier,et al.  Natural killer cells and other innate lymphoid cells in cancer , 2018, Nature Reviews Immunology.

[52]  F. Marincola,et al.  Unleashing endogenous TNF-alpha as a cancer immunotherapeutic , 2018, Journal of Translational Medicine.

[53]  R. Locksley,et al.  Innate Lymphoid Cells: 10 Years On , 2018, Cell.

[54]  V. Velcheti,et al.  Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors , 2018, Clinical Cancer Research.

[55]  L. Moretta,et al.  Nidogen-1 is a novel extracellular ligand for the NKp44 activating receptor , 2018, Oncoimmunology.

[56]  Santosh Kumar.  Natural killer cell cytotoxicity and its regulation by inhibitory receptors , 2018, Immunology.

[57]  Hans Anton Schlößer,et al.  Cytokine release syndrome , 2018, Journal of Immunotherapy for Cancer.

[58]  J. Wagner,et al.  First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. , 2018, Blood.

[59]  L. Deangelis,et al.  Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. , 2018, Cancer discovery.

[60]  M. Colonna.  Innate Lymphoid Cells: Diversity, Plasticity, and Unique Functions in Immunity. , 2018, Immunity.

[61]  S. Asthana,et al.  A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments , 2018, Nature Medicine.

[62]  B. Iacopetta,et al.  Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis , 2018, Oncotarget.

[63]  M. Oliveira,et al.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion , 2018, Front. Immunol..

[64]  M. Robinson,et al.  ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. , 2018, The Lancet. Oncology.

[65]  Charles H. Yoon,et al.  Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity , 2018, Science.

[66]  Jun Huang,et al.  CD8+ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy. , 2018, Current opinion in chemical engineering.

[67]  Jeffrey S. Miller,et al.  Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells , 2018, Cancer Immunology, Immunotherapy.

[68]  E. Sahai,et al.  NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control , 2018, Cell.

[69]  A. Zhavoronkov,et al.  Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy , 2018, Nature Communications.

[70]  H. Ljunggren,et al.  Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML , 2018, Clinical Cancer Research.

[71]  F. Donskov,et al.  A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1 , 2018, Acta oncologica.

[72]  Amanda R. Campbell,et al.  Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function , 2018, Clinical Cancer Research.

[73]  D. Fremont,et al.  Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor , 2017, Cell.

[74]  Manish R. Patel,et al.  A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors , 2017, Clinical Cancer Research.

[75]  E. Sherwood,et al.  Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent. , 2017, Cytokine & growth factor reviews.

[76]  B. Tavitian,et al.  Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis , 2017, Nature Communications.

[77]  S. Caillat-Zucman,et al.  Control of NK Cell Activation by Immune Checkpoint Molecules , 2017, International journal of molecular sciences.

[78]  Shu-Ming Sun,et al.  CCR10 activation stimulates the invasion and migration of breast cancer cells through the ERK1/2/MMP‐7 signaling pathway , 2017, International immunopharmacology.

[79]  A. Lundqvist,et al.  Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma , 2017, Journal of Immunotherapy for Cancer.

[80]  L. Galluzzi,et al.  Control of Metastasis by NK Cells. , 2017, Cancer cell.

[81]  Katayoun Rezvani,et al.  Engineering Natural Killer Cells for Cancer Immunotherapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[82]  Yu-Hong Chen,et al.  IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[83]  N. Waddell,et al.  Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells , 2017, Nature Immunology.

[84]  S. Regis,et al.  TGF-β1 Downregulates the Expression of CX3CR1 by Inducing miR-27a-5p in Primary Human NK Cells , 2017, Front. Immunol..

[85]  Reinhold Förster,et al.  Mechanisms and Dynamics of T Cell-Mediated Cytotoxicity In Vivo. , 2017, Trends in immunology.

[86]  Z. Tian,et al.  Diversity of tissue-resident NK cells. , 2017, Seminars in immunology.

[87]  A. Santoro,et al.  Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. , 2017, The Lancet. Oncology.

[88]  E. Wherry,et al.  Deep immune profiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule expression patterns. , 2017, Journal of immunological methods.

[89]  C. Watzl,et al.  LFA-1 Activation in NK Cells and Their Subsets: Influence of Receptors, Maturation, and Cytokine Stimulation , 2017, The Journal of Immunology.

[90]  Meijuan Huang,et al.  High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer , 2017, Oncoimmunology.

[91]  G. Bernardini,et al.  Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization during Diseases , 2016, Front. Immunol..

[92]  Camille Guillerey,et al.  Targeting natural killer cells in cancer immunotherapy , 2016, Nature Immunology.

[93]  Jeffrey S. Miller,et al.  Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise? , 2016, Clinical Cancer Research.

[94]  M. Schilham,et al.  Human Circulating and Tissue-Resident CD56bright Natural Killer Cell Populations , 2016, Front. Immunol..

[95]  R. Childs,et al.  Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma , 2016, Clinical Cancer Research.

[96]  K. Curran,et al.  Toxicity and management in CAR T-cell therapy , 2016, Molecular therapy oncolytics.

[97]  David K. Finlay,et al.  TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway , 2016, Science Signaling.

[98]  Lewis L. Lanier,et al.  NK cells and cancer: you can teach innate cells new tricks , 2015, Nature Reviews Cancer.

[99]  G. Bernardini,et al.  Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment. , 2015, Cancer research.

[100]  João Moura,et al.  Chemokine Receptor Expression on Normal Blood CD56+ NK-Cells Elucidates Cell Partners That Comigrate during the Innate and Adaptive Immune Responses and Identifies a Transitional NK-Cell Population , 2015, Journal of immunology research.

[101]  Sébastien Gadat,et al.  Individual Human Cytotoxic T Lymphocytes Exhibit Intraclonal Heterogeneity during Sustained Killing. , 2015, Cell reports.

[102]  M. Caligiuri,et al.  A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma , 2015, Clinical Cancer Research.

[103]  F. Souza-Fonseca-Guimaraes,et al.  NK cells require IL-28R for optimal in vivo activity , 2015, Proceedings of the National Academy of Sciences.

[104]  F. Souza-Fonseca-Guimaraes,et al.  DNAM-1 expression marks an alternative program of NK cell maturation. , 2015, Cell reports.

[105]  Benjamin G. Gowen,et al.  A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection , 2015, Science.

[106]  M. Krummel,et al.  The Emerging Understanding of Myeloid Cells as Partners and Targets in Tumor Rejection , 2015, Cancer Immunology Research.

[107]  Y. Qi,et al.  Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+ T and NK Cells , 2015, The Journal of Immunology.

[108]  G. Matarese,et al.  Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumor infiltrated lymph nodes of melanoma patients , 2014, Nature Communications.

[109]  Sebastian Amigorena,et al.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.

[110]  A. Santoni,et al.  c‐Cbl regulates MICA‐ but not ULBP2‐induced NKG2D down‐modulation in human NK cells , 2014, European journal of immunology.

[111]  A. Rudensky,et al.  Interactions between innate and adaptive lymphocytes , 2014, Nature Reviews Immunology.

[112]  D. Campana,et al.  Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. , 2014, Blood.

[113]  S. Rajagopalan.  HLA-G-mediated NK cell senescence promotes vascular remodeling: implications for reproduction , 2014, Cellular and Molecular Immunology.

[114]  R. Braylan,et al.  A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma , 2014, Haematologica.

[115]  H. Ikeda,et al.  Interleukin-17D mediates tumor rejection through recruitment of natural killer cells. , 2014, Cell reports.

[116]  P. Paul,et al.  CD56brightPerforinlow Noncytotoxic Human NK Cells Are Abundant in Both Healthy and Neoplastic Solid Tissues and Recirculate to Secondary Lymphoid Organs via Afferent Lymph , 2014, The Journal of Immunology.

[117]  D. Raulet,et al.  NK cell self tolerance, responsiveness and missing self recognition. , 2014, Seminars in immunology.

[118]  F. Souza-Fonseca-Guimaraes,et al.  The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions , 2014, Nature Immunology.

[119]  G. Berchem,et al.  The Critical Role of the Tumor Microenvironment in Shaping Natural Killer Cell-Mediated Anti-Tumor Immunity , 2013, Front. Immunol..

[120]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[121]  C. Sautès-Fridman,et al.  Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin , 2013, Clinical Cancer Research.

[122]  F. Locatelli,et al.  Neuroblastoma-Derived TGF-β1 Modulates the Chemokine Receptor Repertoire of Human Resting NK Cells , 2013, The Journal of Immunology.

[123]  Paul J. Choi,et al.  Imaging burst kinetics and spatial coordination during serial killing by single natural killer cells , 2013, Proceedings of the National Academy of Sciences.

[124]  Z. Berneman,et al.  Interferon α may be back on track to treat acute myeloid leukemia , 2013, Oncoimmunology.

[125]  Sumati Rajagopalan,et al.  Controlling natural killer cell responses: integration of signals for activation and inhibition. , 2013, Annual review of immunology.

[126]  D. Campana,et al.  A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. , 2013, Cancer research.

[127]  J. Schoenen.  “L’union fait la force” , 2013, Acta Neurologica Belgica.

[128]  Björn Önfelt,et al.  Classification of human natural killer cells based on migration behavior and cytotoxic response. , 2013, Blood.

[129]  W. Al-Herz,et al.  Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production. , 2013, Blood.

[130]  R. Sun,et al.  Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice. , 2013, Gastroenterology.

[131]  J. Lee,et al.  High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor‐infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma , 2012, Journal of surgical oncology.

[132]  P. Nelson,et al.  Recruitment of Natural Killer Cells in Advanced Stages of Endogenously Arising B-cell Lymphoma: Implications for Therapeutic Cell Transfer , 2012, Journal of immunotherapy.

[133]  V. Pistoia,et al.  Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells. , 2011, Blood.

[134]  Lewis L. Lanier,et al.  NK cell development, homeostasis and function: parallels with CD8+ T cells , 2011, Nature Reviews Immunology.

[135]  R. Ferris,et al.  Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity , 2011, Immunologic research.

[136]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[137]  R. Schreiber,et al.  Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.

[138]  P. Bousso,et al.  Intravital imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression. , 2010, Immunity.

[139]  R. Jacobs,et al.  Murine CXCR3+CD27bright NK cells resemble the human CD56bright NK‐cell population , 2010, European journal of immunology.

[140]  M. Nussenzweig,et al.  Origin and development of dendritic cells , 2010, Immunological reviews.

[141]  C. Pui,et al.  NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  E. Carosella,et al.  Human melanoma cell secreting human leukocyte antigen-G5 inhibit natural killer cell cytotoxicity by impairing lytic granules polarization toward target cell. , 2009, Human immunology.

[143]  M. Caligiuri,et al.  Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. , 2009, Blood.

[144]  E. Kimby,et al.  Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. , 2009, Immunotherapy.

[145]  Eric Vivier,et al.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans , 2009, The Journal of experimental medicine.

[146]  S. Ferrini,et al.  NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs. , 2009, International immunology.

[147]  F. Balkwill.  Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[148]  Y. Tsutsumi,et al.  NK cells are migrated and indispensable in the anti-tumor activity induced by CCL27 gene therapy , 2009, Cancer Immunology, Immunotherapy.

[149]  Joseph C. Sun,et al.  Adaptive Immune Features of Natural Killer Cells , 2009, Nature.

[150]  A. Cerwenka,et al.  Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. , 2008, Cancer research.

[151]  J. Orange.  Formation and function of the lytic NK-cell immunological synapse , 2008, Nature Reviews Immunology.

[152]  P. Delvenne,et al.  Innate lymphocyte and dendritic cell cross‐talk: a key factor in the regulation of the immune response , 2008, Clinical and experimental immunology.

[153]  K. Skak,et al.  Interleukin‐21 activates human natural killer cells and modulates their surface receptor expression , 2008, Immunology.

[154]  R. Maruyama,et al.  Increased Expression of Fractalkine is Correlated with a Better Prognosis and an Increased Number of Both CD8+ T Cells and Natural Killer Cells in Gastric Adenocarcinoma , 2008, Annals of Surgical Oncology.

[155]  G. Altavilla,et al.  Natural killer cells infiltrating human nonsmall‐cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells , 2008, Cancer.

[156]  F. Schmidt.  Meta-Analysis , 2008 .

[157]  Michael Hallek,et al.  Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. , 2007, Immunity.

[158]  F. Geissmann,et al.  The trafficking of natural killer cells , 2007, Immunological reviews.

[159]  R. Schreiber,et al.  Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function1 , 2007, The Journal of Immunology.

[160]  M. Parmentier,et al.  The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. , 2007, Blood.

[161]  S. Nutt,et al.  Functional subsets of mouse natural killer cells , 2006, Immunological reviews.

[162]  S. Welte,et al.  Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction , 2006, Nature Immunology.

[163]  N. Zavazava,et al.  Soluble HLA‐G Molecules Induce Apoptosis in Natural Killer Cells , 2006, American journal of reproductive immunology.

[164]  C. Rubini,et al.  Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. , 2006, European journal of cancer.

[165]  M. Smyth,et al.  CD27 Dissects Mature NK Cells into Two Subsets with Distinct Responsiveness and Migratory Capacity1 , 2006, The Journal of Immunology.

[166]  L. Zitvogel,et al.  Natural-killer cells and dendritic cells: "l'union fait la force". , 2005, Blood.

[167]  D. Busch,et al.  DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. , 2005, Blood.

[168]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[169]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[170]  M. Smyth,et al.  TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. , 2005, Blood.

[171]  M. Smyth,et al.  The role of natural killer cells in tumor control—effectors and regulators of adaptive immunity , 2005, Springer Seminars in Immunopathology.

[172]  Eric Vivier,et al.  Natural Killer Cell Signaling Pathways , 2004, Science.

[173]  Jianping Pan,et al.  Interferon-γ is an autocrine mediator for dendritic cell maturation , 2004 .

[174]  H. Ljunggren,et al.  NK Cell TRAIL Eliminates Immature Dendritic Cells In Vivo and Limits Dendritic Cell Vaccination Efficacy 1 , 2004, The Journal of Immunology.

[175]  U. Koszinowski,et al.  Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses , 2003 .

[176]  Y. Tsutsumi,et al.  Antitumor effect by interleukin-11 receptor alpha-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector. , 2003, Cancer research.

[177]  J. Trapani,et al.  Cutting Edge: Granzymes A and B Are Not Essential for Perforin-Mediated Tumor Rejection , 2003, The Journal of Immunology.

[178]  L. Moretta,et al.  The natural killer cell‐mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig‐like receptors , 2003, European journal of immunology.

[179]  L. Moretta,et al.  The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells , 2003, European journal of immunology.

[180]  M. Colonna,et al.  NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation , 2002, Nature Immunology.

[181]  É. Vivier,et al.  Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D , 2002, Nature Immunology.

[182]  Diego Piccioli,et al.  Contact-dependent Stimulation and Inhibition of Dendritic Cells by Natural Killer Cells , 2002, The Journal of experimental medicine.

[183]  W. Yokoyama,et al.  Specific and nonspecific NK cell activation during virus infection , 2001, Nature Immunology.

[184]  L. Lanier,et al.  Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[185]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[186]  James J. Campbell,et al.  Unique Subpopulations of CD56+ NK and NK-T Peripheral Blood Lymphocytes Identified by Chemokine Receptor Expression Repertoire1 , 2001, The Journal of Immunology.

[187]  M. Giga,et al.  The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. , 2001, The Journal of thoracic and cardiovascular surgery.

[188]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[189]  M. Smyth,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis , 2001, The Journal of experimental medicine.

[190]  K. Nakachi,et al.  Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population , 2000, The Lancet.

[191]  T. Mcclanahan,et al.  Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. , 2000, Immunity.

[192]  S. Natsugoe,et al.  Prognostic value of intratumoral natural killer cells in gastric carcinoma , 2000, Cancer.

[193]  H. Ljunggren,et al.  Targeting of human dendritic cells by autologous NK cells. , 1999, Journal of immunology.

[194]  E. Carbone,et al.  Recognition of autologous dendritic cells by human NK cells , 1999, European journal of immunology.

[195]  P. Ricciardi-Castagnoli,et al.  Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo , 1999, Nature Medicine.

[196]  B. Pulendran,et al.  Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[197]  G. Fleuren,et al.  Characteristics of tumor infiltration by adoptively transferred and endogenous natural‐killer cells in a syngeneic rat model: Implications for the mechanism behind anti‐tumor responses , 1998, International journal of cancer.

[198]  G. Trinchieri,et al.  Differentiation of human NK cells into NK1 and NK2 subsets. , 1998, Journal of immunology.

[199]  J. Altman,et al.  Mouse CD94/NKG2A Is a Natural Killer Cell Receptor for the Nonclassical Major Histocompatibility Complex (MHC) Class I Molecule Qa-1b , 1998, The Journal of experimental medicine.

[200]  M. Ross,et al.  Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. , 1998, Journal of immunology.

[201]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[202]  J. Bell,et al.  HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C , 1998, Nature.

[203]  N. Bander,et al.  MHC class I and II expression in prostate carcinoma and modulation by interferon‐alpha and ‐gamma , 1997, The Prostate.

[204]  B. Seliger,et al.  IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[205]  P. Allavena,et al.  IL-2-regulated expression of the monocyte chemotactic protein-1 receptor (CCR2) in human NK cells: characterization of a predominant 3.4-kilobase transcript containing CCR2B and CCR2A sequences. , 1997, Journal of immunology.

[206]  M. Wilders-Truschnig,et al.  Differential phenotypic properties of human peripheral blood CD56dim+ and CD56bright+ natural killer cell subpopulations. , 1996, International archives of allergy and immunology.

[207]  K. Tanaka,et al.  Newly identified pair of proteasomal subunits regulated reciprocally by interferon gamma , 1996, The Journal of experimental medicine.

[208]  P. Allavena,et al.  Induction of natural killer cell migration by monocyte chemotactic protein−1, −2 and −3 , 1994, European journal of immunology.

[209]  R. Schreiber,et al.  Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity. , 1985, Journal of immunology.

[210]  H. Majima.  [Phase I clinical study]. , 1984, Gan to kagaku ryoho. Cancer & chemotherapy.

[211]  Jeffrey S. Miller,et al.  Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells. , 2016, Methods in molecular biology.

[212]  T. Waldmann,et al.  Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[213]  N. Rouas-Freiss,et al.  HLA-G: An Immune Checkpoint Molecule. , 2015, Advances in immunology.

[214]  M. Caligiuri,et al.  A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. , 2012, Blood.

[215]  Margaret Comerford Freda,et al.  10 Years. , 2008, MCN. The American journal of maternal child nursing.

[216]  L. Trümper.  From bench to bedside , 2005, Medizinische Klinik.

[217]  F. Tanaka,et al.  The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. , 2005, International journal of oncology.

[218]  M. Smyth,et al.  Induction of tumor-specific T cell memory by NK cell–mediated tumor rejection , 2002, Nature Immunology.

[219]  S. Coca,et al.  Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. , 2002, Lung cancer.

[220]  R. Vance,et al.  Regulation of the natural killer cell receptor repertoire. , 2001, Annual review of immunology.

[221]  久松浩.  Newly Identified Pair of Proteasomal Subunits Regulated Reciprocally by Interferon γ , 1997 .